86 related articles for article (PubMed ID: 30396570)
21. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
22. Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec).
Samoszuk M; Corwin MA
Int J Cancer; 2003 Sep; 106(5):647-52. PubMed ID: 12866022
[TBL] [Abstract][Full Text] [Related]
23. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167
[TBL] [Abstract][Full Text] [Related]
24. Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
Koppenhagen P; Dickreuter E; Cordes N
Radiother Oncol; 2017 Sep; 124(3):370-378. PubMed ID: 28578803
[TBL] [Abstract][Full Text] [Related]
25. Extracellular matrix secreted by senescent fibroblasts induced by UVB promotes cell proliferation in HaCaT cells through PI3K/AKT and ERK signaling pathways.
Kang J; Chen W; Xia J; Li Y; Yang B; Chen B; Sun W; Song X; Xiang W; Wang X; Wang F; Bi Z; Wan Y
Int J Mol Med; 2008 Jun; 21(6):777-84. PubMed ID: 18506372
[TBL] [Abstract][Full Text] [Related]
26. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
[TBL] [Abstract][Full Text] [Related]
27. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
28. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
29. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
[TBL] [Abstract][Full Text] [Related]
30. Carnosic acid, a phenolic diterpene from rosemary, prevents UV-induced expression of matrix metalloproteinases in human skin fibroblasts and keratinocytes.
Park M; Han J; Lee CS; Soo BH; Lim KM; Ha H
Exp Dermatol; 2013 May; 22(5):336-41. PubMed ID: 23614740
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Roy M; Sarkar R; Mukherjee A; Mukherjee S
Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
[TBL] [Abstract][Full Text] [Related]
32. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
[TBL] [Abstract][Full Text] [Related]
33. Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells.
Wei Y; To KK; Au-Yeung SC
J Pharmacol Sci; 2015 Dec; 129(4):210-5. PubMed ID: 26644081
[TBL] [Abstract][Full Text] [Related]
34. Trichostatin a prevents TGF-beta1-induced apoptosis by inhibiting ERK activation in human renal tubular epithelial cells.
Yoshikawa M; Hishikawa K; Idei M; Fujita T
Eur J Pharmacol; 2010 Sep; 642(1-3):28-36. PubMed ID: 20553909
[TBL] [Abstract][Full Text] [Related]
35. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.
Vuorinen K; Gao F; Oury TD; Kinnula VL; Myllärniemi M
Exp Lung Res; 2007 Sep; 33(7):357-73. PubMed ID: 17849262
[TBL] [Abstract][Full Text] [Related]
36. Protective effects of polyvinylpyrrolidone-wrapped fullerene against intermittent ultraviolet-A irradiation-induced cell injury in HaCaT cells.
Saitoh Y; Ohta H; Hyodo S
J Photochem Photobiol B; 2016 Oct; 163():22-9. PubMed ID: 27522271
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
[TBL] [Abstract][Full Text] [Related]
38. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
Kirschner KM; Baltensperger K
Mol Cancer Res; 2003 Nov; 1(13):970-80. PubMed ID: 14638869
[TBL] [Abstract][Full Text] [Related]
39. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
Larmonier N; Janikashvili N; LaCasse CJ; Larmonier CB; Cantrell J; Situ E; Lundeen T; Bonnotte B; Katsanis E
J Immunol; 2008 Nov; 181(10):6955-63. PubMed ID: 18981115
[TBL] [Abstract][Full Text] [Related]
40. Alpha 3 beta 1 integrin promotes keratinocyte cell survival through activation of a MEK/ERK signaling pathway.
Manohar A; Shome SG; Lamar J; Stirling L; Iyer V; Pumiglia K; DiPersio CM
J Cell Sci; 2004 Aug; 117(Pt 18):4043-54. PubMed ID: 15280429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
